Welcome to UCL Cancer Institute
The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing kinder, more effective therapies for cancer patients. If you are thinking about studying with us, applications to our flagship MSc Cancer postgraduate programme and our new undergraduate degree BSc Cancer Biomedicine, are now open to application for September 2018 start.
News and features
The Tumour Heterogeneity Team, led by Professor Charles Swanton, has been awarded the Cancer Research UK Translational Research Prize at the National Cancer Research Institute (NCRI) conference 2017. This prize recognises the cutting edge breakthroughs of an outstanding research team that has united in the quest to ensure scientific discoveries benefit patients and the public.
Published: Dec 11, 2017 4:26:10 PM
Researchers from UCL, the German Center for Neurodegenerative Diseases (DZNE) and McGill University, Montreal have published details of a novel laboratory model that replicates the hallmarks of paediatric brain cancer. The research results, published in Cancer Cell, could pave the way for a better understanding of processes driving the development of cancer.
Published: Oct 31, 2017 11:09:38 AM
Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver.
Published: Oct 11, 2017 12:17:24 PM
The highly anticipated results from the ARIEL3 clinical trial, evaluating use of rucaparib among women with advanced ovarian cancer, have been published in The Lancet. According to study data, maintenance therapy with rucaparib (Rubraca, Clovis Oncology) significantly extended progression-free survival among women with platinum-sensitive recurrent ovarian cancer.
Published: Oct 1, 2017 2:29:11 PM
A University College Hospital prostate cancer patient has undergone diagnosis using hyperpolarised Magnetic Resonance Imaging (MRI) as part of a UCL clinical trial. Led by Dr Shonit Punwani, the trial aims to develop more accurate and personalised treatment for cancer.
Published: Aug 23, 2017 4:17:30 PM
Support our work
Help us to continue the research that will lead to the breakthroughs in therapies for cancer patients. Support us >
Action for equality and diversity
UCL Cancer Institute is proud to hold an Athena SWAN silver award in recognition of our commitment to advancing equality, diversity and inclusion.